Chad Waite is a general partner with OVP Venture Partners. He joined OVP in 1987 and focuses on investments in the digital biology, and network security sectors. His investments include 4thPass, Accelerator, Adapx, Airgo Networks, Boston Beer, Cardima, CellPro, CODA Genomics, Complete Genomics, Corixa, Serengeti, Etera, Filenet, GenoLogics, GreaterGood.com, Loudeye Technologies, NanoString, Napera Networks, Plectix BioSystems, ProTools, Quantum Medical, Raytel Medical, Returns Online, Rosetta Inpharmatics, SafeHarbor, Saros, Seattle Genetics, SignalSoft, Syntellect, Vantos, Verity, and WatchGuard. He currently serves on the Board of Directors of Accelerator, Adapx, CODA Genomics, Complete Genomics, GenoLogics, NanoString, Napera Networks, Plectix BioSystems, and SafeHarbor and is a Board Observer to Allozyne, Orb Networks Recodagen and Talyst.
Prior to joining OVP, Chad was a General Partner at Hambrecht & Quist Venture Partners where he focused on investments in IT and life sciences. Prior to H&Q, he was in marketing and sales management at Cobe Laboratories, Inc. in its cardiovascular medical products division.
Chad received his BA in History from Kenyon College and his MBA from Harvard Business School. He is a board member of the NVCA and the Washington Technology Alliance. He is a Trustee at Kenyon College, a member of the Oregon Health Sciences University (OHSU) BSIF Advisory Board and a member of the University of Washington's Technology Transfer Advisory Board. He is the proud father of three grown children, is an avid cyclist and snowboarder, and loves fine wine.